Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473882 | 0.93 | CYP2D6 (0.46) | CYP2D6CYP2C19HPGDEPHX2RECQL | |
| SCHEMBL17660269 | 0.81 | HPGD (0.50) | CYP2D6CYP2C19HPGDEPHX2RECQL | |
| SCHEMBL19818495 | 0.79 | CYP2D6 (0.45) | CYP2D6CYP2C19HPGDEPHX2PSMB5 | |
| SCHEMBL9153250 | 0.79 | HPGD (0.47) | CYP2D6CYP2C19HPGDEPHX2RECQL | |
| SCHEMBL9162003 | 0.79 | HPGD (0.47) | CYP2D6CYP2C19HPGDEPHX2RECQL | |
| SCHEMBL25760230 | 0.78 | CYP2D6 (0.43) | CYP2D6CYP2C19HPGDEPHX2PSMB5 | |
| SCHEMBL18965507 | 0.78 | CYP2D6 (0.43) | CYP2D6CYP2C19HPGDEPHX2RECQL | |
| SCHEMBL20034806 | 0.77 | EPHX2 (0.47) | CYP2D6CYP2C19HPGDEPHX2RECQL | |
| SCHEMBL24465646 | 0.77 | RECQL (0.41) | PSMB5RECQLMLYCD | |
| SCHEMBL20805872 | 0.77 | CYP2C19 (0.46) | CYP2D6CYP2C19HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | CYP2D6 439/4885CYP2C19 370/4885HPGD 344/4885 |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | PREP, VIP, PEPD | CYP2D6 439/4885CYP2C19 370/4885HPGD 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.